Calamos Conv. Opptys. & Income Fund (CHI) At $11.23 Forms Top; Kadmon Holdings INC. Common Sto (KDMN) Shorts Up By 18.06%

November 15, 2017 - By Ellis Scott

Calamos Conv. Opptys. & Income Fund (CHI) formed multiple top with $12.24 target or 9.00% above today’s $11.23 share price. Calamos Conv. Opptys. & Income Fund (CHI) has $786.36M valuation. The stock decreased 0.62% or $0.07 during the last trading session, reaching $11.23. About shares traded. Calamos Conv. Opptys. & Income Fund (NASDAQ:CHI) has risen 13.66% since November 15, 2016 and is uptrending. It has underperformed by 3.04% the S&P500.

Kadmon Holdings INC. Common Sto (NYSE:KDMN) had an increase of 18.06% in short interest. KDMN’s SI was 1.53M shares in November as released by FINRA. Its up 18.06% from 1.30 million shares previously. With 216,800 avg volume, 7 days are for Kadmon Holdings INC. Common Sto (NYSE:KDMN)’s short sellers to cover KDMN’s short positions. The stock decreased 0.14% or $0.01 during the last trading session, reaching $3.59. About shares traded. Kadmon Holdings Inc (NYSE:KDMN) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 6 analysts covering Kadmon Holdings (NYSE:KDMN), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Kadmon Holdings had 7 analyst reports since August 22, 2016 according to SRatingsIntel. The firm has “Buy” rating given on Monday, August 22 by Jefferies. JMP Securities initiated Kadmon Holdings Inc (NYSE:KDMN) on Monday, August 22 with “Outperform” rating. The firm has “Buy” rating by H.C. Wainwright given on Monday, August 22. The stock of Kadmon Holdings Inc (NYSE:KDMN) earned “Buy” rating by H.C. Wainwright on Monday, June 26. On Friday, March 24 the stock rating was maintained by Piper Jaffray with “Overweight”. The stock has “Neutral” rating by Citigroup on Monday, August 22. WBB Securities upgraded it to “Hold” rating and $3.25 target in Thursday, March 16 report.

Kadmon Holdings, Inc. is an integrated biopharmaceutical firm engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The company has market cap of $282.33 million. The Firm is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. It currently has negative earnings. The Company’s product pipeline consists of KD025, Tesevatinib and KD034.

Investors sentiment increased to 1.46 in Q2 2017. Its up 0.52, from 0.94 in 2017Q1. It increased, as 8 investors sold Calamos Conv. Opptys. & Income Fund shares while 16 reduced holdings. 7 funds opened positions while 28 raised stakes. 9.06 million shares or 15.29% less from 10.69 million shares in 2017Q1 were reported. Janney Montgomery Scott Limited Liability Company holds 0% of its portfolio in Calamos Conv. Opptys. & Income Fund (NASDAQ:CHI) for 34,608 shares. Cambridge Rech holds 0% of its portfolio in Calamos Conv. Opptys. & Income Fund (NASDAQ:CHI) for 30,144 shares. Hollencrest Secs Ltd Co holds 0.09% of its portfolio in Calamos Conv. Opptys. & Income Fund (NASDAQ:CHI) for 54,275 shares. Whittier Trust Company has invested 0% in Calamos Conv. Opptys. & Income Fund (NASDAQ:CHI). Bellecapital Intll Ltd holds 0.17% or 17,525 shares. Bb&T Secs Ltd Company holds 22,689 shares. Envestnet Asset invested in 0% or 318 shares. 11,592 were accumulated by Mariner Wealth Advisors Limited Liability Corporation. Northwestern Mutual Wealth Mgmt Company holds 12,730 shares or 0% of its portfolio. Moreover, Sigma Planning has 0.09% invested in Calamos Conv. Opptys. & Income Fund (NASDAQ:CHI). Kansas-based Creative Planning has invested 0% in Calamos Conv. Opptys. & Income Fund (NASDAQ:CHI). Cetera Advisors accumulated 60,979 shares. Raymond James Associates accumulated 0% or 66,977 shares. Deutsche Comml Bank Ag stated it has 2 shares or 0% of all its holdings. The New York-based Oppenheimer has invested 0% in Calamos Conv. Opptys. & Income Fund (NASDAQ:CHI).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ellis Scott




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: